Dashboard › Demo Universe › Halcyon Medical Devices
Halcyon Medical Devices · HLCN
DEMO DATAUNDERWRITING ASSUMPTIONHOLDFinancial statements DEMO DATA ANALYST PROJECTION
| $M | FY2022A | FY2023A | FY2024A | FY2025A | FY2026E | FY2027E | FY2028E | FY2029E | FY2030E |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.2B | $1.3B | $1.3B | $1.4B | $1.3B | $1.3B | $1.3B | $1.4B | $1.4B |
| % growth | 6.8% | 5.6% | 5.3% | -4.2% | -2.1% | 2.5% | 2.0% | 2.0% | |
| Direct costs / COGS | $407.1M | $428.4M | $445.5M | $476.0M | $476.1M | $474.0M | $481.8M | $487.3M | $492.9M |
| Gross profit (NOI for real estate) | $772.9M | $831.6M | $884.5M | $924.0M | $865.1M | $839.0M | $864.0M | $885.4M | $907.4M |
| % margin | 65.5% | 66.0% | 66.5% | 66.0% | 64.5% | 63.9% | 64.2% | 64.5% | 64.8% |
| Operating expenses (cash, adjusted) | $495.6M | $529.2M | $558.6M | $588.0M | $563.3M | $551.5M | $565.3M | $576.6M | $588.1M |
| EBITDA (company-adjusted basis) | $277.3M | $302.4M | $325.8M | $336.0M | $301.8M | $287.6M | $298.8M | $308.9M | $319.3M |
| % margin | 23.5% | 24.0% | 24.5% | 24.0% | 22.5% | 21.9% | 22.2% | 22.5% | 22.8% |
| D&A | $53.1M | $56.7M | $59.8M | $63.0M | $60.4M | $59.1M | $60.6M | $61.8M | $63.0M |
| Share-based compensation | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| EBIT | $224.2M | $245.7M | $266.0M | $273.0M | $241.4M | $228.5M | $238.2M | $247.1M | $256.2M |
| Interest expense | $50.2M | $53.2M | $56.1M | $59.1M | $65.1M | $63.8M | $62.4M | $62.1M | $29.5M |
| EBT | $174.0M | $192.5M | $209.9M | $213.9M | $176.3M | $164.7M | $175.8M | $185.0M | $226.7M |
| Taxes | $43.5M | $48.1M | $52.5M | $53.5M | $44.1M | $41.2M | $43.9M | $46.3M | $56.7M |
| Net income (model basis) | $130.5M | $144.4M | $157.4M | $160.4M | $132.2M | $123.5M | $131.8M | $138.8M | $170.1M |
| Capex | $47.2M | $50.4M | $53.2M | $56.0M | $51.0M | $49.9M | $51.1M | $52.2M | $53.2M |
| Working capital & other cash items | $6.7M | $9.6M | $8.4M | $8.4M | ($4.4M) | ($0.8M) | $6.6M | $6.0M | $6.1M |
| Free cash flow | $129.6M | $141.1M | $155.6M | $159.0M | $146.0M | $133.5M | $134.6M | $142.4M | $173.8M |
Historical columns are fictional demo inputs. Projections flow from the selected scenario’s assumptions (Scenarios tab): interest accrues on beginning balances by tranche; floating tranches use MAX(SOFR, floor) + spread + scenario shock; PIK accrues to principal. FCF = net income + D&A + SBC + PIK − capex − ΔNWC / other. Impairments, restructuring and other one-offs are excluded from EBITDA and net income and sit in the cash plug.
Sources & data lineage (3)
| Source | Document | Data type | Period | Accession | Doc date | Retrieved | Class |
|---|---|---|---|---|---|---|---|
| CreditIQ demo dataset | Halcyon Medical Devices — illustrative financial statements FY2022–FY2025 | Income statement / cash flow | FY2022–FY2025 | — | 2026-03-31 | 2026-03-31 | DEMO DATA |
| CreditIQ demo dataset | Halcyon Medical Devices — illustrative capital structure & covenants | Debt schedule | As of 2026-03-31 | — | 2026-03-31 | 2026-03-31 | DEMO DATA |
| CreditIQ demo dataset | Illustrative indicative bid marks (% of par) | Market price | 2026-03-31 | — | 2026-03-31 | 2026-03-31 | DEMO DATA |